Observational studyInternal and emergency medicine2021
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities.
Observational study in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Epidemiology of idiopathic pulmonary fibrosis: a population registry-based study.Orphanet journal of rare diseases · 2026Article
- Article
- Clinical characteristics and all-cause mortality in female patients with idiopathic pulmonary fibrosis in Chinese population.Journal of global health · 2025Article
- Changes in lung function and exercise capacity are strong predictors of mortality in patients with IPF receiving antifibrotic therapy.Frontiers in medicine · 2025Article
- Prevalence, Clinical Features, and Outcomes of Young Patients with Idiopathic Pulmonary Fibrosis.Respiration; international review of thoracic diseases · 2025Article
- Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data.Advances in therapy · 2024Article
- Diabetes mellitus and idiopathic pulmonary fibrosis: a Mendelian randomization study.BMC pulmonary medicine · 2024Article
- Lung function trajectories in patients with idiopathic pulmonary fibrosis.Respiratory research · 2023Observational
- The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Editorial: Idiopathic pulmonary fibrosis: epidemiology, prognosis and treatment.Frontiers in medicine · 2023Article
- Prognosis and Survival in Idiopathic Pulmonary Fibrosis in the Era of Antifibrotic Therapy in Italy: Evidence from a Longitudinal Population Study Based on Healthcare Utilization Databases.International journal of environmental research and public health · 2022Observational
- Higher susceptibility of males to bleomycin-induced pulmonary inflammation is associated with sex-specific transcriptomic differences in myeloid cells.Toxicology and applied pharmacology · 2022Article
- Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases.BMC pulmonary medicine · 2022Article
- Left-sided heart failure burden and mortality in idiopathic pulmonary fibrosis: a population-based study.BMC pulmonary medicine · 2022Article
- Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review.Upsala journal of medical sciences · 2022Review
- Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?Frontiers in medicine · 2021Article
- Harnessing the ECM Microenvironment to Ameliorate Mesenchymal Stromal Cell-Based Therapy in Chronic Lung Diseases.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Placebo arms of clinical trials provide an opportunity to investigate the natural history of idiopathic pulmonary fibrosis (IPF) but these patients are not representative of the real life IPF population. Objective of this article is to evaluate patients' characteristics of incident IPF cases and their impact on mortality and hospitalizations risk. We conducted a retrospective cohort study using data from administrative databases from 2000 to 2010. Based on different algorithms reported in literature, incident IPF cases were identified. We applied Cox proportional hazards models to assess relationship between patients' characteristics, mortality and hospitalization. According to three case definitions, we identified 2338, 460 and 1704 incident IPF cases. Mean age at diagnosis was about 72 years, the proportion of male varied between 59 and 62% and patients with at least one chronic disease were between 70 and 74%. Age, male sex and comorbidities were associated to worse outcomes. Congestive heart failure (CHF), diabetes and cancer were conditions associated to mortality, while those associated to hospitalization were CHF and chronic obstructive pulmonary disease. Our data source provided one of the largest samples of unselected patients with a long follow-up period. Using different algorithms proposed and validated in literature, we observed that mortality and hospitalization rate are high in patients with IPF and age, sex and comorbidities significantly affect clinical outcomes. Females show a significant survival advantage over males, even after adjusting for age and comorbidities. Patients with pre-existing diseases, especially those with pulmonary and cardiovascular diseases are at higher risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.